P181 Bactericidal/ permeability-increasing protein is present in plasma of stable and exacerbating COPD patients
Wong YY. et al, (2024), ‘Catching Fire’ – Measuring and targeting inflammation in COPD, A216.1 - A216
S63 Eosinophilic inflammation at exacerbations of COPD is associated with less dynamic troponin rises in the 30 days post exacerbation
Dobson P. et al, (2024), ‘Firestarter’ – Inflammation, mechanisms and biomarkers in COPD, A49.1 - A49
S109 Treating eosinophilic exacerbations of asthma and COPD with benralizumab: a double blind, double dummy, active-placebo controlled randomised trial (ABRA)
Ramakrishnan S. et al, (2024), ‘The Famous Five’ – Emerging clinical trial data, A76.2 - A77
T6 Exhaled nitric oxide (FeNO) predicts clinical and anti-inflammatory response to prednisolone for breakthrough attacks in anti-IL5/IL5R treated asthma
Howell I. et al, (2024), BTS/BALR/A+LUK Early Career Investigator Award Symposium, A5.2 - A6
Watchful waiting in laryngo‐tracheobronchial amyloid: A case report
Beinart D. et al, (2024), Respirology Case Reports, 12
RCT Abstract - Treating eosinophilic exacerbations of asthma and COPD with benralizumab: a double-blind, double-dummy, active-placebo randomised controlled trial (ABRA)
Ramakrishanan S. et al, (2024), Airway pharmacology and treatment, RCT3716 - RCT3716
Blood eosinophils and lung function loss: from passive prediction to active prevention?
Ramakrishnan S. et al, (2024), European Respiratory Journal, 63, 2400812 - 2400812
Coordinated nasal mucosa-mediated immunity accelerates recovery from COVID-19.
Cass SP. et al, (2024), ERJ open research, 10, 919 - 2023
Multiple Event-time Analysis: A New Approach for Event Based Clinical Trials in Obstructive Airway Diseases
Ramakrishnan S. et al, (2024), A101. FULL METAL JACKET TARGETING COPD AND CHRONIC AIRWAYS DISEASE, A2794 - A2794
Predicting Severe Asthma Attacks With Blood Eosinophils and Exhaled Nitric Oxide (FeNO): Initial Data Analysis for the ORACLE Patient-level Meta-analysis
Couillard S. et al, (2024), C31. WHAT'S NEW IN CLINICAL ASTHMA, A5274 - A5274
Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial.
Ramakrishnan S. et al, (2024), The Lancet. Respiratory medicine, 12, 67 - 77
How have we measured trial outcomes of asthma attack treatment? A systematic review.
Howell I. et al, (2024), ERJ open research, 10, 660 - 2023
Trailblazing Clinical Trials in Asthma, COPD, Sleep Medicine, and Education and Clinical Practice in 2023.
Farmer MJS. et al, (2024), Chest, 165, 19 - 21
Prednisolone for COPD exacerbations: time for a rethink.
Ramakrishnan S., (2023), ERJ open research, 9, 464 - 2023
Patients’ acceptance of outcome and experience measurements during hospitalisation for COPD exacerbations: a CICERO Clinical Research Collaboration–European Lung Foundation online patient survey
Gyselinck I. et al, (2023), ERJ Open Research, 9, 00148 - 2023
Recovery of Breakthrough Asthma Attacks Treated With Oral Steroids While on Monoclonal Antibody Therapy: Protocol for a Prospective Observational Study (BOOST)
Howell I. et al, (2023), JMIR Research Protocols, 12, e46741 - e46741
Chronic obstructive pulmonary disease: 10 years of precision-guided success
Ramakrishnan S., (2023), The Lancet Respiratory Medicine, 11, 227 - 228